1.Studies on the inhibition of polyhydroxylated aromatic compounds against HIV-1 integrase.
Zhi-min GUO ; Hong-shan CHEN ; Lin WANG
Acta Pharmaceutica Sinica 2002;37(4):253-256
AIMThree major enzymes of HIV-1, reverse transcriptase (RT), protease (PR), and integrase (IN), are important targets for anti-HIV drugs. Nine RT and five PR inhibitors have been effectively used in treatment of AIDS patients. In order to find active integrase inhibitors, twenty polyhydroxylated aromatic compounds were tested.
METHODSELISA method was used to test the integrase activity. The synthesized donor substrate oligonucleotide representing the HIV-1 U5LTR was immobilized onto Covalink polystyrene microtiter plates, and a synthesized biotinlated 20 bp oligonucleotide was used as the target substrate. The products were detected and quantified by a colorimetric avidin-linked alkaline phosphatase reporter system.
RESULTSCompound NQ-2 was found to inhibit HIV-1 integrase with the IC50 of 78.5 mumol.L-1 by ELISA method. Its novel analogue NQ-3 was found to be 2 fold more potent on HIV intrgrase than NQ-2, IC50 was 37.2 mumol.L-1. The IC50s of NQ-2 and NQ-3 to inhibit the 3'-pro + assembly activity of integrase were 96.94 mumol.L-1 and 8.48 mumol.L-1; to inhibit assembly activity were 168 and 6.9 mumol.L-1 and to inhibit strand-transfer activity were 49.8 and 1.1 mumol.L-1, respectively. Compound NQ-2 mostly inhibited the strand transfer activity of HIV-1 integrase. Compound NQ-3 inhibited both the assembly and strand-transfer with high activities.
CONCLUSIONNaphthoquinone compound NQ-3 was found to be a novel HIV integrase inhibitor which warrants further study. Uncoupled ELISA HIV integrase assay is shown to be useful to screen HIV-1 integrase inhibitors.
Coumarins ; pharmacology ; HIV Integrase ; drug effects ; metabolism ; HIV Integrase Inhibitors ; pharmacology ; HIV-1 ; drug effects ; enzymology ; Inhibitory Concentration 50 ; Naphthoquinones ; pharmacology ; Polycyclic Aromatic Hydrocarbons ; pharmacology ; Stilbenes ; pharmacology
2.Design, synthesis of quinolinone acid-containing compounds with anti-HIV integrase activity.
Xiao-fang CHEN ; Yan-bin WU ; Jie JIN ; Rui-zhen WANG ; Chong WANG ; Jun LIU
Acta Pharmaceutica Sinica 2010;45(2):263-267
A series of novel quinolinone acid-containing compounds were designed and synthesized. Their structures were confirmed with 1H NMR and MS. The target compounds were tested for anti-HIV-1 integrase activities in vitro with enzyme linked immunosorbent assay (ELISA). The result showed that D-2, D-4 and D-7 have anti-integrase activity with IC50 < 100 micromol L(-1).
HIV Integrase
;
metabolism
;
HIV Integrase Inhibitors
;
chemical synthesis
;
chemistry
;
pharmacology
;
Inhibitory Concentration 50
;
Quinolones
;
chemical synthesis
;
chemistry
;
pharmacology
;
Structure-Activity Relationship
3.Research progress of dual inhibitors targeting HIV-1 reverse transcriptase and integrase.
Hong LIU ; Peng ZHAN ; Xin-Yong LIU
Acta Pharmaceutica Sinica 2013;48(4):466-476
Both reverse transcriptase (RT) and integrase (IN) play crucial roles in the life cycle of HIV-1, which are also key targets in the area of anti-HIV drug research. Reverse transcriptase inhibitors are involved in the most employed drugs used to treat AIDS patients and HIV-infected people, while one of the integrase inhibitors has already been approved by US FDA to appear on the market. Great achievement has been made in the research on both, separately. Recently, much more attention of medicinal chemistry researchers has been attracted to the strategies of multi-target drugs. Compounds with excellent potency against both HIV RT and IN, evidently defined as dual inhibitors targeting both enzymes, have been obtained through considerable significant exploration, which can be classified into two categories according to different strategies. Combinatorial chemistry approach together with high throughput screening methods and multi-target-based virtual screening strategy have been useful tools for identifying selective anti-HIV compounds for long times; Rational drug design based on pharmacophore combination has also led to remarkable results. In this paper, latest progress of both categories in the discovery and structural modification will be covered, with a view to contribute to the career of anti-HIV research.
Drug Design
;
HIV Integrase Inhibitors
;
chemistry
;
pharmacology
;
HIV Reverse Transcriptase
;
antagonists & inhibitors
;
HIV-1
;
drug effects
;
Humans
;
Molecular Structure
;
Reverse Transcriptase Inhibitors
;
chemistry
;
pharmacology
;
Structure-Activity Relationship
4.Advances in the study of HIV-1 integrase inhibitors of alpha, gamma-diketo compounds.
Sheng-hui YU ; Yan-mei TAN ; Gui-sen ZHAO
Acta Pharmaceutica Sinica 2010;45(2):215-223
HIV-1 integrase (IN) is an essential enzyme for retroviral replication. There is no analogue for this enzyme in human cells so that inhibition of IN will not bring strong effect on human body. Thus, HIV-1 IN has become a rational target for therapy of AIDS. This review provides a comprehensive report of alpha, gamma-diketo IN inhibitors discovered in recent years. Compilation of such data will prove to be beneficial in developing QSAR, pharmacophore hypothesis generation and validation, virtual screening and synthesis of compounds with higher activity.
Anti-HIV Agents
;
chemical synthesis
;
chemistry
;
pharmacology
;
HIV Integrase
;
chemistry
;
physiology
;
HIV Integrase Inhibitors
;
chemical synthesis
;
chemistry
;
pharmacology
;
HIV-1
;
drug effects
;
Humans
;
Keto Acids
;
chemical synthesis
;
chemistry
;
pharmacology
;
Molecular Structure
;
Quantitative Structure-Activity Relationship
5.HIV-1 integrase enzyme linked immunosorbent assay and inhibitors.
Chinese Journal of Experimental and Clinical Virology 2002;16(2):119-123
BACKGROUNDTo establish an ELISA method for detecting the activity of HIV-1 integrase and screening of inhibitors.
METHODSHIV recombinant plasmid F185K/C280S IN1-288 was transformed into the E.coli strain BL21(DE3) integrase with a histag was induced by adding isopropyl-?-D?thiogalactopyranoside (IPTG)and purified by nickel affinity chromatography. The synthesized donor substrate oligonucleotide representing the HIV-1 U5LTR was immobilized onto covalink polystyrene microtiter plates, and a synthesized biotinlated 20 bp oligonucleotide was used as the target substrate. The products were detected and quantified using a colorimetic avidin?linked alkaline phosphatase reporter system,and identified by 32? autoradiography. Some natural products and chemically synthesized compounds were screened for HIV-1 integrase inhibitors.
RESULTSThe purified integrase was identified by SDS?PAGE and showed integration activity by ELISA and?32P radioisotopic assay.?Coefficients of variation (CV)of ELISA in a lot and among the lots were 4.63% and 5.89% respectively, the mean of P/N was 2.836 0.161 under the optimal experimental condition. Some plant extracts were found as potent integrase inhibitors. The IC50s for CEH and CEHL were (20.41 5.68)?g/ml and (7.56 1.86)?g/ml respectively.
CONCLUSIONSThe authors have established a simple and rapid ELISA method with stable repeatability for detecting integrase activity, which can be used for screening and studying of specific inhibitors of HIV-1 integrase.
Antiviral Agents ; pharmacology ; Drug Evaluation, Preclinical ; Enzyme-Linked Immunosorbent Assay ; methods ; HIV Integrase ; isolation & purification ; metabolism ; HIV Integrase Inhibitors ; pharmacology ; HIV-1 ; enzymology ; Recombinant Fusion Proteins ; isolation & purification ; metabolism
6.Advances in the study of HIV-1 integrase inhibitor of aryl beta-diketoacids.
Acta Pharmaceutica Sinica 2006;41(9):801-807
Animals
;
Anti-HIV Agents
;
chemistry
;
pharmacology
;
Furans
;
pharmacology
;
HIV Integrase Inhibitors
;
chemistry
;
pharmacology
;
HIV-1
;
drug effects
;
Humans
;
Keto Acids
;
chemistry
;
pharmacology
;
Molecular Structure
;
Naphthyridines
;
pharmacology
;
Triazoles
;
pharmacology
7.Wikstroelide M potently inhibits HIV replication by targeting reverse transcriptase and integrase nuclear translocation.
Xuan ZHANG ; Sheng-Zhuo HUANG ; Wan-Gang GU ; Liu-Meng YANG ; Huan CHEN ; Chang-Bo ZHENG ; You-Xing ZHAO ; David Chi-Cheong WAN ; Yong-Tang ZHENG
Chinese Journal of Natural Medicines (English Ed.) 2014;12(3):186-193
AIM:
To evaluate the anti-HIV activity and mechanism of action of wikstroelide M, a daphnane diterpene from Daphne acutiloba Rehder (Thymelaeaceae).
METHODS:
The anti-HIV activities of wikstroelide M against different HIV strains were evaluated by cytopathic effect assay and p24 quantification assay with ELISA. The inhibitory effect of wikstroelide M on HIV reverse transcription was analyzed by real-time PCR and ELISA. The effect of wikstroelide M on HIV-1 integrase nuclear translocation was observed with a cell-based imaging assay. The effect of wikstroelide M on LEDGF/p75-IN interaction was assayed by molecular docking.
RESULTS:
Wikstroelide M potently inhibited different HIV-1 strains, including HIV-1IIIB, HIV-1A17, and HIV-19495, induced a cytopathic effect, with EC50 values ranging from 3.81 to 15.65 ng·mL⁻¹. Wikstroelide M also had high inhibitory activities against HIV-2ROD and HIV-2CBL-20-induced cytopathic effects with EC50 values of 18.88 and 31.90 ng·mL⁻¹. The inhibitory activities of wikstroelide M on the three HIV-1 strains were further confirmed by p24 quantification assay, with EC50 values ranging from 15.16 to 35.57 ng·mL⁻¹. Wikstroelide M also potently inhibited HIV-1IIIB induced cytolysis in MT-4 cells, with an EC50 value of 9.60 ng·mL⁻¹. The mechanistic assay showed that wikstroelide M targeted HIV-1 reverse transcriptase and nuclear translocation of integrase through disrupting the interaction between integrase and LEDGF/p75.
CONCLUSION
Wikstroelide M may be a potent HIV-1 and HIV-2 inhibitor, the mechanisms of action may include inhibition of reverse trascriptase activity and inhibition of integrase nuclear translocation through disrupting the interaction between integrase and LEDGF/p75.
Anti-HIV Agents
;
pharmacology
;
therapeutic use
;
Cell Line
;
Daphne
;
chemistry
;
Diterpenes
;
pharmacology
;
HIV Infections
;
drug therapy
;
virology
;
HIV Integrase
;
metabolism
;
HIV Integrase Inhibitors
;
pharmacology
;
therapeutic use
;
HIV Reverse Transcriptase
;
antagonists & inhibitors
;
HIV-1
;
drug effects
;
enzymology
;
HIV-2
;
drug effects
;
Humans
;
Intercellular Signaling Peptides and Proteins
;
metabolism
;
Phytotherapy
;
Plant Extracts
;
pharmacology
;
therapeutic use
;
Virus Integration
;
drug effects
;
Virus Replication
;
drug effects
8.Isolation, idetification and anti-HIV-1 integrase activity of culturable endophytic fungi from Tibetan medicinal plant Phlomis younghusbandii Mukerjee.
Da-Wei ZHANG ; Ming-Ming ZHAO ; Juan CHEN ; Chao LI ; Shun-Xing GUO
Acta Pharmaceutica Sinica 2013;48(5):780-789
A total of 52 endophytic fungi were isolated from roots and stems of Tibetan medicinal plant Phlomis younghusbandii Mukerjee. These fungal isolates were molecularly identified based on ITS sequnces and 28S sequences distributed to 12 genera, including Phoma, Chaetosphaeronema, Fusarium and Leptosphaeria, etc. Among them, the dominant genus was Phoma. Extracts of all strains were evaluated for anti-HIV-1 integrase activity by using soluable integrase expressed in E. coli BL21 (DE3). The results showed that seven samples from five fungal endophytes PHY-24, PHY-38, PHY-40, PHY-51, PHY-53, which belonged to genus Chaetosphaeronema, inhibited strand transfer reaction catalyzed by HIV-1 integrase with IC50 values, of 6.60, 5.20, 2.86, 7.86, 4.47, 4.56 and 3.23 microg x mL(-1) respectively. In conclusion, the endophytic fungi of Phlomis younghusbandii Mukerjee are valuable for further screening anti-HIV-1 integrase agents.
Ascomycota
;
enzymology
;
isolation & purification
;
Chaetomium
;
enzymology
;
isolation & purification
;
Endophytes
;
enzymology
;
isolation & purification
;
Escherichia coli
;
enzymology
;
HIV Integrase
;
genetics
;
metabolism
;
HIV Integrase Inhibitors
;
pharmacology
;
Phlomis
;
microbiology
;
Phylogeny
;
Plant Roots
;
microbiology
;
Plant Stems
;
microbiology
;
Plants, Medicinal
;
microbiology
;
Plasmids
;
Recombinant Proteins
;
genetics
;
metabolism
9.The in vitro HAART pharmacodynamics study with dolutegravir as the "anchor".
Acta Pharmaceutica Sinica 2015;50(1):50-58
This study is to evaluate the HAART pharmacodynamics with dolutegravir as the "anchor" in vitro. A nucleoside reverse transcriptase inhibitors (NRTIs) resistant recombinant virus model (VSVG/HIV-1(RT-D67N,K70R,T215F)) and an integrase inhibitors (INIs) resistant recombinant virus model (VSVG/HIV-1(IN-G140S,QI48H)) were constructed and established. The anti-viral pharmacodynamics was evaluated with drug combinations including two NRTIs along with one INI or one NNRTI. The results showed that the combination with an INI gave a stronger synergism on wild type HIV-1 replication comparing to that with an NNRTI. Comparing the two INIs as the "anchor" for HAART, DTG exhibited an equivalent CI to that of RAL on wild type HIV-1 replication; but a greater synergy than RAL on INI-resistant HIV-1 replication. Besides of the pharmacodynamics results of DTG-based drug combination, the results may contribute to clinical antiviral therapy.
Antiretroviral Therapy, Highly Active
;
Cells, Cultured
;
Drug Resistance, Viral
;
HIV Integrase Inhibitors
;
pharmacology
;
HIV-1
;
drug effects
;
physiology
;
Heterocyclic Compounds, 3-Ring
;
pharmacology
;
Humans
;
Virus Replication
;
drug effects
10.Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008.
Pu-rong ZHENG ; Hai XUE ; Zhi-yan XIAO ; Gang LIU
Acta Pharmaceutica Sinica 2010;45(2):154-164
HIV and AIDS remain as the crucial global health concern, therefore, research and development of novel anti-HIV-1 chemical therapeutics is still of paramount significance, which may be illuminated by cases of successful marketed drugs. Herein, we document the discovery and biological profile of new anti-HIV-1 drugs approved by FDA between 2005 and 2008 and some drug candidates are also discussed.
Acquired Immunodeficiency Syndrome
;
drug therapy
;
Anti-HIV Agents
;
chemistry
;
pharmacology
;
therapeutic use
;
HIV Fusion Inhibitors
;
chemistry
;
pharmacology
;
therapeutic use
;
HIV Infections
;
drug therapy
;
HIV Integrase Inhibitors
;
chemistry
;
pharmacology
;
therapeutic use
;
HIV Protease Inhibitors
;
chemistry
;
pharmacology
;
therapeutic use
;
HIV-1
;
drug effects
;
Humans
;
Molecular Structure
;
Reverse Transcriptase Inhibitors
;
chemistry
;
pharmacology
;
therapeutic use